Celgene closed at $68.13 in the latest trading session, marking a -0.1% move from the prior day. This change was narrower than the S&P 500's 2.08% loss on the day. Elsewhere, the Dow lost 2.11%, while the tech-heavy Nasdaq lost 2.27%.
Prior to today's trading, shares of the biotechnology company had lost 2.54% over the past month. This has lagged the Medical sector's loss of 1.48% and was narrower than the S&P 500's loss of 3.6% in that time.
CELG will be looking to display strength as it nears its next earnings release, which is expected to be January 24, 2019. The company is expected to report EPS of $2.31, up 15.5% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.97 billion, up 14% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.80 per share and revenue of $15.20 billion, which would represent changes of +18.28% and +16.93%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CELG. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CELG currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CELG currently has a Forward P/E ratio of 7.75. This represents a discount compared to its industry's average Forward P/E of 21.68.
It is also worth noting that CELG currently has a PEG ratio of 0.36. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.48 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Image: Bigstock
Celgene (CELG) Stock Moves -0.1%: What You Should Know
Celgene closed at $68.13 in the latest trading session, marking a -0.1% move from the prior day. This change was narrower than the S&P 500's 2.08% loss on the day. Elsewhere, the Dow lost 2.11%, while the tech-heavy Nasdaq lost 2.27%.
Prior to today's trading, shares of the biotechnology company had lost 2.54% over the past month. This has lagged the Medical sector's loss of 1.48% and was narrower than the S&P 500's loss of 3.6% in that time.
CELG will be looking to display strength as it nears its next earnings release, which is expected to be January 24, 2019. The company is expected to report EPS of $2.31, up 15.5% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $3.97 billion, up 14% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.80 per share and revenue of $15.20 billion, which would represent changes of +18.28% and +16.93%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for CELG. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. CELG currently has a Zacks Rank of #3 (Hold).
Digging into valuation, CELG currently has a Forward P/E ratio of 7.75. This represents a discount compared to its industry's average Forward P/E of 21.68.
It is also worth noting that CELG currently has a PEG ratio of 0.36. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.48 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 63, which puts it in the top 25% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.